Ignite Creation Date:
2024-05-19 @ 5:33 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06412965
Status:
COMPLETED
Last Update Posted:
2024-06-26
First Post:
2024-04-16
Brief Title:
Reliability of Rimegepant or Triptans for the Acute Treatment of Migraine
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Evaluation of the Reliability of Effect of Rimegepant for the Acute Treatment of Migraine Across Multiple Attacks
Status:
COMPLETED
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Adelphi DSP
Brief Summary:
This protocol describes the analysis of the Adelphi Real World ARW Migraine Disease Specific ProgrammeTM 2022 a cross-sectional study which used both physician and patient surveys to assess the perception of the acute treatment for migraine attacks
Detailed Description:
This is a retrospective database study that aims to explore the reliability of effect with acute use of Rimegepant or triptans to evaluate the satisfaction with Rimegepant or triptans to evaluate willingness to continue using Rimegepant or triptans and to explore proportion optimized on treatment with Rimegepant or triptans The data will be extracted from the Adelphi Real World ARW Migraine Disease Specific ProgrammeTM DSP 2022 database which was conducted across a number of countries including United States between May 2022 and November 2022 The DSP was an observational study of clinical practice Treatment practice data were collected by physicians physician survey who were asked to provide information for the next 10 patients consulting for migraine These patients were then invited to fill out a self-completion form patient survey providing their own assessment on the disease and treatments
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None